{"id":5263,"date":"2016-04-01T11:51:58","date_gmt":"2016-04-01T08:51:58","guid":{"rendered":"http:\/\/www.ced.org.tr\/?p=5263"},"modified":"2016-04-01T15:09:59","modified_gmt":"2016-04-01T12:09:59","slug":"novartisin-yolsuzluk-iddiasi","status":"publish","type":"post","link":"http:\/\/www.ced.org.tr\/?p=5263","title":{"rendered":"Novartis\u2019in Yolsuzluk \u0130ddias\u0131"},"content":{"rendered":"<p style=\"text-align: left;\" align=\"right\"><span style=\"font-size: xx-large;\">Novartis\u2019in T\u00fcrkiye\u2019de r\u00fc\u015fvetle 85 milyon dolarl\u0131k i\u015f ald\u0131\u011f\u0131 iddia ediliyor<\/span><\/p>\n<p style=\"text-align: left;\" align=\"right\">\u00a0<span style=\"color: #757575;\"><span style=\"font-size: large;\">31 mart 2016 -H\u00fcrriyet<\/span><\/span><span style=\"color: #454545;\"><span style=\"font-size: large;\">Haberler<\/span><\/span><\/p>\n<p style=\"text-align: left;\" align=\"right\"><span style=\"font-size: medium;\"><span style=\"font-family: pt sansbold italic;\">\u0130svi\u00e7reli ila\u00e7 \u015firketi Novartis, T\u00fcrkiye\u2019de r\u00fc\u015fvet da\u011f\u0131tarak 85 milyon dolarl\u0131k i\u015f almak ve rekabet avantaj\u0131 sa\u011flamakla su\u00e7lan\u0131yor. Ge\u00e7ti\u011fimiz hafta \u00c7in\u2019de r\u00fc\u015fvet vermekten 460 milyon dolar cezaya \u00e7arpt\u0131r\u0131lan Novartis iddialar\u0131 ara\u015ft\u0131rd\u0131\u011f\u0131n\u0131 a\u00e7\u0131klad\u0131.<\/span><\/span><\/p>\n<p style=\"text-align: left;\" align=\"right\">Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 bir ila\u00e7 \u015firketinin T\u00fcrkiye&#8217;de r\u00fc\u015fvet da\u011f\u0131tarak i\u015f ald\u0131\u011f\u0131 iddialar\u0131n\u0131n ihbar olarak kabul edildi\u011fini ve inceleme ba\u015flat\u0131ld\u0131\u011f\u0131n\u0131 belirtti. Novartis T\u00fcrkiye konuyla ilgili yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, iddialar\u0131n as\u0131ls\u0131z oldu\u011funu belirtti.<\/p>\n<div class=\"news-box\">\n<p class=\"selectionShareable\">Bakanl\u0131\u011f\u0131n yapt\u0131\u011f\u0131 yaz\u0131l\u0131 a\u00e7\u0131klamada \u015firket ismi belirtilmedi,ancak Reuters bu hafta isimsiz bir ihbarc\u0131n\u0131n \u0130svi\u00e7re merkezli ila\u00e7 \u015firketi Novartis&#8217;i bir dan\u0131\u015fmanl\u0131k \u015firketi \u00fczerinden T\u00fcrkiye&#8217;de r\u00fc\u015fvet da\u011f\u0131tarak toplam 85 milyon dolar de\u011ferinde yeni i\u015f ve rekabet avantaj\u0131 sa\u011flamak ile su\u00e7lad\u0131\u011f\u0131n\u0131 bildirmi\u015fti.<\/p>\n<p class=\"selectionShareable\">Bakanl\u0131\u011f\u0131n yapt\u0131\u011f\u0131 yaz\u0131l\u0131 a\u00e7\u0131klamada, &#8220;Bas\u0131na yans\u0131yan s\u00f6z konusu iddialar ihbar olarak kabul edilmi\u015f olup, bakanl\u0131\u011f\u0131m\u0131z denetim elemanlar\u0131 marifetiyle b\u00fcy\u00fck bir titizlik ve hassasiyetle incelenip, soru\u015fturulacakt\u0131r. \u0130nceleme sonucunda herhangi bir suistimalin tespit edilmesi halinde gerekli idari ve adli i\u015flemler derhal yap\u0131lacakt\u0131r&#8221; denildi.<\/p>\n<p class=\"selectionShareable\"><strong>NOVART\u0130S T\u00dcRK\u0130YE&#8217;DEN A\u00c7IKLAMA GELD\u0130<\/strong><\/p>\n<p class=\"selectionShareable\">Novartis T\u00fcrkiye, konuyla ilgili olarak a\u00e7\u0131klama yapt\u0131.<\/p>\n<p class=\"selectionShareable\">\u015eirketten yap\u0131lan a\u00e7\u0131klamada, \u201cNovartis T\u00fcrkiye ile ilgili iddialar as\u0131ls\u0131z ve eski bir \u015fikayete dayan\u0131yor. \u00c7al\u0131\u015fma Bakanl\u0131\u011f\u0131\u2019n\u0131n 2014\u2019teki soru\u015fturmas\u0131nda iddialar\u0131n as\u0131ls\u0131z oldu\u011fu sonucuna var\u0131ld\u0131\u201d denildi.<\/p>\n<\/div>\n<p align=\"right\"><span style=\"font-size: medium;\"><span style=\"font-family: pt sansbold italic;\">.<\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis\u2019in T\u00fcrkiye\u2019de r\u00fc\u015fvetle 85 milyon dolarl\u0131k i\u015f ald\u0131\u011f\u0131 iddia ediliyor \u00a031 mart 2016 -H\u00fcrriyetHaberler \u0130svi\u00e7reli ila\u00e7 \u015firketi Novartis, T\u00fcrkiye\u2019de r\u00fc\u015fvet&#46;&#46;&#46;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[62],"tags":[],"class_list":["post-5263","post","type-post","status-publish","format-standard","hentry","category-sagliktan-haberler"],"aioseo_notices":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/5263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5263"}],"version-history":[{"count":4,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/5263\/revisions"}],"predecessor-version":[{"id":5267,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/5263\/revisions\/5267"}],"wp:attachment":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5263"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}